An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers

Publisher： Karger

E-ISSN： 1423-0232|57|3|202-210

ISSN： 0030-2414

Source： Oncology, Vol.57, Iss.3, 1999-10, pp. : 202-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

By  

Oncology, Vol. 58, Iss. 3, 2000-04 ,pp. : 191-197

Karger

Access to resources Recommend Favorite

Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 49-52

Karger

Access to resources Recommend Favorite

Phase I/II Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 219-225

Karger

Access to resources Recommend Favorite

Prevention of Peritoneal Metastasis of Human Gastric Cancer Cells in Nude Mice by S-1, a Novel Oral Derivative of 5-Fluorouracil

By  

Oncology, Vol. 64, Iss. 2, 2003-02 ,pp. : 176-182

Karger

Access to resources Recommend Favorite

A phase II study of oral S‐1 with concurrent radiotherapy followed by chemotherapy with S‐1 alone for locally advanced pancreatic cancer

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 19, Iss. 2, 2012-03 ,pp. : 152-158

John Wiley & Sons Inc

Access to resources Recommend Favorite